An outbreak of hepatitis C virus attributed to the use of multi-dose vials at a colonoscopy clinic, Waterloo Region, Ontario

Arianne Folkema¹*, Hsiu-Li Wang¹,², Kristy Wright¹, M Mustafa Hirji²,³, Anton Andonov⁴, Kathryn Bromley¹, Chad Ludwig¹, Amy MacArthur¹

Abstract

Background: Hepatitis C virus (HCV) transmission has been epidemiologically linked to healthcare settings, particularly out-of-hospital settings such as endoscopy clinics and hemodialysis clinics. These have been largely attributed to lapses in infection prevention and control practices (IPAC).

Objective: To describe the public health response to an outbreak of HCV that was detected among patients of a colonoscopy clinic in Ontario, and to highlight the risks of using multi-dose vials and the need for improved IPAC practices in out-of-hospital settings.

Methods: Screening for HCV was conducted on patients and staff who attended or worked at the clinic within the same timeframe as the index case’s procedure. Blood samples from positive cases underwent viral sequencing. Inspections of the clinic assessed IPAC practices, and a chart review was done to identify plausible mechanisms for transmission.

Outcome: A total of 38% of patients who underwent procedures at the clinic on the same day as the index case tested positive for HCV. Genetic sequencing showed a high degree of similarity in the HCV genetic sequence among the samples positive for HCV. Chart review and clinic inspection identified use of multi-dose vials of anesthesia medication across multiple patients as the plausible mechanism for transmission.

Conclusion: Healthcare workers, especially those in out-of-hospital procedural/surgical premises, should be vigilant in following IPAC best practices, including those related to the use of multi-dose vials, to prevent the transmission of bloodborne infections in healthcare settings.

Suggested citation: Folkema A, Wang HL, Wright K, Hirji MM, Andonov A, Bromley K, Ludwig C, MacArthur A. An outbreak of hepatitis C virus attributed to the use of multi-dose vials at a colonoscopy clinic, Waterloo Region, Ontario. Can Commun Dis Rep 2021;47(4):224–31. https://doi.org/10.14745/ccdr.v47i04a07

Keywords: HCV, infection prevention and control practices, IPAC, contamination, outbreak, out-of-hospital healthcare settings

Introduction

About 246,000 Canadians were living with chronic hepatitis C virus (HCV) infection in 2011 (1).

HCV is a bloodborne virus, and the most common modes of infection are through using drug paraphernalia contaminated with infected blood, receiving body services (e.g. tattooing) that use unsanitary tools or work practices, or sharing personal care items (2).

HCV outbreaks have been epidemiologically linked to healthcare settings in Canada and elsewhere, particularly out-of-hospital surgical/procedural settings such as endoscopy clinics and hemodialysis clinics (3–16). Transmission in these settings has been attributed to syringe reuse; contamination of medication vials used on multiple patients; storage and preparation of medication, intravenous solution and injections in a contaminated environment; and other infection prevention
and control (IPAC) lapses that resulted in the contamination of injectable medications or flush solution used for multiple patients (3–16).

The purpose of this report is to:

- Describe the public health response to this outbreak of HCV in a colonoscopy clinic
- Highlight the risk of using multi-dose vials
- Show the need for continued improvement in IPAC practices in out-of-hospital settings

**Background**

As mandated through the *Health Protection and Promotion Act*, HCV is a reportable disease and Ontario public health departments must investigate all new diagnoses of HCV that occur within their jurisdiction (17,18).

Region of Waterloo Public Health and Emergency Services (hereafter referred to as Public Health), in southern Ontario, coordinates the public health activities for its urban and rural population of approximately 550,000. As part of its reportable disease investigation, Public Health follows up with all HCV cases to identify possible sources of infection and to take measures to prevent further spread (18).

**Methods**

**Detection of the outbreak**

In October 2014, during a routine follow-up with an individual who had been recently diagnosed with HCV and who had previously tested negative for HCV through repeat blood donation screening, Public Health identified that this individual’s only risk factor was a procedure at a colonoscopy clinic on December 24, 2013. All other HCV cases reported within the jurisdiction since January 1, 2010 (the year the clinic opened) were subsequently reviewed to determine if other cases had identified colonoscopy as a risk factor.

The review identified a second individual who had been reported to Public Health earlier in 2014 and who had also undergone a procedure on the same day at the same clinic. Although this person had been born in an endemic country, they had no other obvious risk factors. Given that the two cases shared a common risk factor and were linked by time and place, an outbreak was suspected and further investigation was conducted. Blood samples from the two identified HCV cases were obtained and sent to the National Microbiology Laboratory of the Public Health Agency of Canada in Winnipeg for genotyping and sequencing.

**Investigation**

Public Health used the Centers for Disease Control and Prevention (CDC) *Viral hepatitis: Healthcare Investigation Guide* and documentation from a previous health care–associated investigation as guidance for a systematic approach to the investigation and public health response to this outbreak (19,20).

Patient lists for December 23 and 24, 2013 were obtained from the colonoscopy clinic and the provincial reportable diseases database was searched to determine whether any other cases of HCV reported in the province had undergone procedures at the clinic since its inception on October 14, 2010. Patient screening was not conducted for the two-day interval before and after December 23 and 24, 2013 because the clinic was closed on December 21 and 22 (a Saturday and a Sunday), and December 25 and 26 (statutory holidays).

As per the Public Health Ontario Laboratory Protocol for HCV testing, patients were first screened for HCV antibodies using an anti-hepatitis C antibody assay; those with anti-hepatitis C antibodies then had HCV antibody supplemental testing performed for confirmation (21). Any patients with positive results on the confirmatory testing then had new samples submitted for molecular testing for HCV ribonucleic acid RNA and genotyping.

Public Health conducted a search on the College of Physicians and Surgeons of Ontario’s (CPSO) website to confirm that all physicians working at the clinic on December 23 and 24, 2013 held valid professional licences and to determine if any previous IPAC violations had been reported.

Public Health staff contacted all patients who underwent procedures at the clinic on December 23 and 24, 2013 and recommended HCV screening. Daytime and early evening screening clinics were offered locally. For patients who resided outside of the health department’s jurisdiction, Public Health facilitated follow-up with physicians in their areas. Blood samples were submitted to the National Microbiology Laboratory in Winnipeg for HCV testing and positive samples underwent genetic sequencing.

A case was defined as an individual with a laboratory-confirmed HCV infection (both HCV antibody and RNA testing) that had undergone any procedure performed at the clinic on December 23 or 24 that could be associated with disease transmission (colonoscopy, esophagogastroduodenoscopy/ gastroscopy, glucose monitoring and intravenous medication administration).

Between November 17, 2014 and April 21, 2015, Public Health conducted multiple inspections of the clinic to assess and follow-up on IPAC practices. The inspection was guided by a comprehensive assessment tool based on the Ontario Provincial Infectious Diseases Advisory Committee’s (PIDAC) *Infection Prevention and Control for Clinical Office Practice* document (22). Inspections were supplemented by lengthy interviews with staff to understand their processes and IPAC practices. The final inspection was conducted jointly with the CPSO, which has
regulatory oversight over community colonoscopy clinics (public health departments in Ontario only investigate out-of-hospital premises in response to suspected infection control lapses) (23).

The inspections involved observation of high-risk procedures including the preparation and storage of medications; use of multi-dose vials; endoscope reprocessing practices; cleaning and disinfection of surfaces and equipment; use of materials and equipment such as medical gels, intravenous saline flushes and glucometers; as well as a review of the clinic’s IPAC policies and procedures. Several colonoscopy procedures were observed directly to assess the IPAC practices, including anesthesia administration.

An extensive review of all the charts of patients who visited the clinic for procedures on December 23 and 24, 2013 was also conducted to identify patterns that might indicate potential routes of transmission. The chart review included review of the time of the visit; procedure room used; endoscope serial number; glucometer use; anesthetic (propofol) dose received; other medications received; and the attending surgeon, anesthesiologist and nursing staff.

Results

In total, 40 individuals underwent procedures at the clinic on December 23 and 24, 2013. Public Health was successful in screening 39 out of the 40 patients and 11 out of 13 staff (Table 1); one patient and two staff could not be contacted. Of the 26 patients who attended and nine staff who worked at the clinic on December 23, all screened negative for HCV. Of the patients who attended the clinic on December 24, 5 out of 13 (38%) tested positive for HCV (Table 2).

Table 1: HCV screening results for staff and patients who attended colonoscopy clinic on December 23 and 24, 2013

| Clinic date | Total | HCV positive | HCV negative | Not screened* |
|-------------|-------|--------------|--------------|--------------|
| **Patients** |       |              |              |              |
| 2013-12-23  | 27    | 0            | 26           | 1            |
| 2013-12-24  | 13    | 5            | 8            | 0            |
| **Total**   | 40    | 5            | 36           | 3            |
| **Staff**   |       |              |              |              |
| 2013-12-23 only | 8 | 0 | 6 | 2 |
| 2013-12-24 only | 2 | 0 | 2 | 0 |
| **Both 2013-12-23 and 2013-12-24** | 3 | 0 | 3 | 0 |
| **Total** | 13 | 5 | 45 | 3 |

None of the staff who worked on December 24 tested positive. The review of all known HCV cases in Ontario since the clinic’s inception in October 2010 did not identify any additional cases of HCV linked to this clinic. The search on the CPSO website indicated that all physicians working at the clinic at the time of the outbreak held valid licences.

Phylogenetic analysis conducted by the National Microbiology Laboratory based on partial sequences from the HCV core (C), envelope (E1) and non-structural (NS5B) genes clearly indicated that the HCV strains from the five outbreak patients were genetically closely related (Figure 1), consistent with a cluster of transmission. All five cases clustered in a monophyletic group based on the E1 gene sequences. A more detailed analysis based on next-generation sequencing (NGS) revealed that the HCV quasispecies population of all five patients clearly clustered together on a single branch with a 99% probability (Figure 2). The average genetic distance within the five cases involved in the outbreak quasispecies was 0.036 while the genetic distance between this group and similar outbreaks as well as unrelated Ontario cases and GenBank HCV strains was significantly higher (p<0.001).

The inspections of the clinic and interviews with staff identified no concerns or deficiencies with respect to the use, cleaning or reprocessing of endoscopes. Glucose monitoring was not performed on all five HCV patients, ruling out the use of a shared glucometer as a potential source of infection. Of the 13 patients who received an intravenous saline flush, only five were HCV positive, which decreased the likelihood that the bag of intravenous saline used for the entire day was a potential source of infection.
The chart review of patients attending the clinic on December 24 showed that only one procedure room was used. All patients who attended the clinic that day had the same surgeon, anesthesiologist and nurses during their procedures. The first 11 patients had the same pre-procedure nurse, while the last two patients had a different pre-procedure nurse. The procedures for the five patients who tested positive for HCV used different endoscopes.

All HCV patients were administered the anesthetic drug, propofol, using multi-dose medication vials across multiple patients, and this was the only plausible mechanism of HCV transmission identified. Based on the amount of propofol administered to each patient according to their medical charts, a patient medication map was developed to present the hypothesized distribution of contaminated 100 mL vials of propofol alongside the distribution of HCV cases at the clinic on December 24, 2013 (Table 3). Since all patients who had a procedure performed also had propofol administered during their procedure, a pattern was identified in the occurrence of HCV positivity and the use of propofol.

As shown in Table 3, it is hypothesized that all 100 mL of the first vial of propofol (Vial #1) was used up on the first five patients, none of whom tested positive for HCV. Then, propofol Vial #2 was contaminated with the blood of patient #6 who had a pre-existing undiagnosed HCV infection. This same vial was then used for patients #7, #8 and #10. Finally, the remaining 15 mL of propofol in Vial #2 was mixed with 5 mL of propofol from a third vial to make 20 mL of propofol for patient #11, thereby contaminating Vial #3 but diluting the amount of contamination. This dilution could explain why only one of the three patients who received propofol from Vial #3 tested positive for HCV.

Given that the actual propofol vial used for each patient was not identified in the patient charts, this interpretation was hypothesized based on the type of vials used by the clinics, the doses administered to the patients as recorded in their charts and finding out from the inspections and interviews that multi-dose vials were being used across multiple patients.
The findings from the outbreak investigation support the hypothesis of HCV transmission from a previously undiagnosed HCV patient to four uninfected persons. Laboratory results demonstrated that all five cases of HCV had genetically related viruses, indicating a high likelihood of transmission from a common source. The investigation identified an association between the administration of propofol from multi-dose vials and the patients who tested positive for HCV.

Contamination of multi-dose vials has been associated with other instances of transmission of bloodborne infections in colonoscopy clinics, among other places (4,8,12,24,25). There is a risk of bloodborne pathogen transmission when devices (e.g. blood glucose monitors) and medications (e.g. multi-dose vials, saline bags) are shared among patients, even in the absence of visible blood on objects (6,25–28).

Out-of-hospital settings may be more vulnerable to infection control lapses than hospitals because specific IPAC resources and

Table 3: Colonoscopy patient medication map for December 24, 2013

| Patient number | Procedure start time | Procedure type | HCV lab result | Medication administered | Total dose administered (mg)ᵃ | Total volume administered (mL)ᵇ | Hypothesized vial # | Hypothesized use of propofol vials (100 mL per vial) |
|----------------|----------------------|----------------|----------------|--------------------------|-------------------------------|-----------------------------|-------------------|--------------------------------------------------|
| 1              | 08:54                | Colonoscopy    | Negative       | Propofol                | 250                           | 25                          | Vial #1           | All 100 mL of the first vial of propofol (Vial #1) was used on the first five patients. |
| 2              | 09:16                | Colonoscopy    | Negative       | Propofol                | 150                           | 15                          |                   |                                                  |
| 3              | 09:54                | Endoscopy      | Negative       | Propofol                | 200                           | 20                          |                   |                                                  |
| 4              | 10:08                | Colonoscopy    | Negative       | Propofol                | 200                           | 20                          |                   |                                                  |
| 5              | 10:42                | Colonoscopy    | Negative       | Propofol                | 200                           | 20                          |                   |                                                  |
| 6              | 11:10                | Endoscopy/colonoscopy | Positive       | Propofol                | 250                           | 25                          | Vial #2           | The second vial of propofol (Vial #2) was contaminated with the blood of Patient #6 with HCV and was then used on Patients #7, #8 and #10. |
| 7              | 11:54                | Colonoscopy    | Positive       | Propofol                | 200                           | 20                          |                   |                                                  |
| 8              | 12:25                | Colonoscopy    | Positive       | Propofol                | 200                           | 20                          |                   |                                                  |
| 9              | N/A                  | IV start only  | Negative       | None                    | None                          | None                        |                   |                                                  |
| 10             | 13:40                | Colonoscopy    | Positive       | Propofol                | 200                           | 20                          |                   |                                                  |
| 11             | 14:10                | Colonoscopy    | Negative       | Propofol                | 200                           | 20                          |                   |                                                  |
| 12             | 14:35                | Endoscopy/colonoscopy | Negative       | Propofol                | 250                           | 25                          | Vial #3           | The last 15 mL of Vial #2 was mixed with 5 mL of propofol from a third vial (Vial #3) to make 20 mL of propofol for Patient #11, thereby contaminating Vial #3, but diluting the amount of contamination. This dilution could explain why only one of the three patients who received propofol from Vial #3 tested positive for HCV. |
| 13             | 15:11                | Colonoscopy    | Positive       | Propofol                | 200                           | 20                          |                   |                                                  |

Abbreviations: HCV, hepatitis C virus; IV, intravenous; N/A, not applicable
ᵃ Dose obtained from patient charts
ᵇ Volume administered was deduced from the dose administered and the concentration of the 100 mL vials of propofol used at the clinic

Discussion

The findings from the outbreak investigation support the hypothesis of HCV transmission from a previously undiagnosed HCV patient to four uninfected persons. Laboratory results demonstrated that all five cases of HCV had genetically related viruses, indicating a high likelihood of transmission from a common source. The investigation identified an association between the administration of propofol from multi-dose vials and the patients who tested positive for HCV.
oversight have been less robust in this practice setting (29,30). Out-of-hospital settings typically do not have on-site infection control specialists, guidance on policies and procedures tailored to their practice setting, requirements to audit staff practices, nor in many jurisdictions, a clear procedure to report and investigate infection control lapses (29).

In addition, non-hospital settings may have physically smaller procedure rooms; this may provide more opportunities for body fluids from patients to contaminate nearby surfaces, supplies and equipment (23,31). In 2014, Canadian hospital operating rooms were a minimum of 400 square feet; in comparison, non-hospital procedure rooms do not have a set minimum size and only require that the space allow for the physician and assisting staff to move around the procedure table with access to the patient without contamination (23,31).

At the time of the outbreak, out-of-hospital premises were inspected only once every five years, which resulted in out-of-date practices, declined adherence to standards of practice over time and/or failure to recognize critical errors in practice for long periods (23,32,33).

It is not routine practice to screen clients for bloodborne pathogens prior to invasive medical procedures, and IPAC procedures have been put in place to prevent transmission of bloodborne pathogens. However, researchers estimate that 44% of Canadians with HCV infection remain undiagnosed due to the asymptomatic nature and slow progression of infection (34). Further, for a sub-group of people born between 1945 and 1975 (“baby boomers”), up to 70% of people who have the virus are unaware of their infection status (34). In its updated guidelines, the Canadian Association for the Study of the Liver has emphasized that healthcare providers should offer HCV testing to people at risk for infection, including baby boomers (35). These updated guidelines for screening could help raise awareness of HCV-positive status prior to medical procedures and contribute to the prevention of bloodborne pathogens in all settings.

Outbreak response challenges
The approaches of Public Health and the regulatory bodies were not necessarily consistent and had to be aligned. Further, knowledge of infection control and prevention best practices varied among healthcare practitioner groups. The IPAC investigation also needed to be conducted while allowing the clinic to continue operating and providing procedures for clients during the investigation.

Finally, at the time of the outbreak, although cases were identified through patient screening, not all cases were eligible for treatment. Fortunately, changes have since been made to the Ontario Drug Benefit to cover the cost of medication for all HCV patients.

Conclusion
This outbreak investigation resulted in increased local and provincial awareness of medication injection safety (23). On April 30, 2015, Public Health Ontario published updated guidance on the use of multi-dose vials. The CPSO adopted the Public Health Ontario best practices guidance as the standard for IPAC in out-of-hospital premises (22). The updated guidelines refer to the overwhelming preference for single-use medication vials and state that multi-dose vials should be restricted to single patients. The guidelines also state that patient safety should be prioritized over cost when choosing between multi-dose and single-use medication vials.

Since this outbreak in 2013, other outbreaks related to IPAC lapses in out-of-hospital premises have occurred in Canada (15,16). Public health investigations of IPAC complaints are also on the rise in Ontario, including in settings where regulated health professionals work (36). Given continued pressures on delivery of health care in Canada and around the world, the number of procedures that occur in out-of-hospital premises could increase, leading to an increased risk of outbreaks if IPAC practices are suboptimal. Careful consideration of IPAC resources, supports and regulations is needed as such an expansion of out-of-hospital premises occurs.

Authors’ statement
AF — Writing–original draft, writing–review & editing
HW — Supervision of outbreak management and public health response, writing–review & editing
KW — Supervision of outbreak management and public health response, writing–review & editing
MH — Investigation, writing–review & editing
AA — Viral sequencing and interpretation, writing–review & editing
KB — Writing–review & editing
CL — Investigation, writing–review & editing
AM — Writing–review & editing

Competing interests
None.

Acknowledgements
We thank Public Health Ontario and the National Microbiology Laboratory of the Public Health Agency of Canada for their expertise and guidance during the investigation. We would also like to thank BM Hutchison and the Sexual Health and Harm Reduction and Infectious Diseases and Tuberculosis Control teams at Region of Waterloo Public Health for their contributions to the investigation of this outbreak.
Funding

This work was supported by the Ontario Ministry of Health and the Region of Waterloo.

References

1. Trubnikov M, Yan P, Archibald C. Estimated prevalence of hepatitis C virus infection in Canada, 2011. Can Commun Dis Rep 2014;40(19):429–36. DOI PubMed

2. Government of Canada. Hepatitis C. Ottawa (ON): Government of Canada; 2016-03-10 (accessed 2021-03-21). http://www.canada.ca/en/health-canada/services-conditions/diseases-conditions/disease-maladies-conditions/hepatitis-c/hepatitis-c.html

3. Germain JM, Carbonne A, Thiers V, Gros H, Chastan S, Bouvet E, Astagneau P. Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia. Infect Control Hosp Epidemiol 2005;26(9):789–92. DOI PubMed

4. Fischer GE, Schaefer MK, Labus BJ, Sands L, Rowley P, Azzam IA, Armour P, Khudyakov YE, Lin Y, Xia G, Patel PR, Perz JF, Holmberg SD. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin Infect Dis 2010;51(3):267–73. DOI PubMed

5. Centers for Disease Control and Prevention (CDC). Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic—Nevada, 2007. MMWR Morb Mortal Wkly Rep 2008;57(19):513–7. PubMed

6. Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks (≥ 2 cases) reported to the Centers for Disease Control and Prevention 2008–2019. Atlanta (GA): CDC; 2015 (accessed 2016-03-21). http://www.cdc.gov/hepatitis/outbreaks/healthcarehepoutbreaktable.htm

7. Heikens E, Hetem DJ, Jousma-Rutjes JP, Nijhuis W, Boland GJ, Hommes NH, Thang OH, Schuurman R. Hepatitis C virus transmission in a Dutch haemodialysis unit: detailed outbreak investigation using NS5A gene sequencing. J Hosp Infect 2019;101(3):333–8. DOI PubMed

8. Chung YS, Choi JY, Han MG, Park KR, Park SJ, Lee H, Jee Y, Kang C. A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea. J Clin Virol 2018;106:53–7. DOI PubMed

9. Coyle JR, Goerge E, Kacynski K, Rodgers R, Raines P, Vail LS, Lowhim S. Hepatitis C virus infections associated with unsafe injection practices at a pain management clinic, Michigan, 2014–2015. Pain Med 2017;18(2):322–9. DOI PubMed

10. Nguyen DB, Gutowski J, Ghiselli M, Cheng T, Bel Hamdounia S, Suryaprasad A, Xu F, Moulton-Meissner H, Hayden T, Forbi JC, Xia GL, Arduino MJ, Patel A, Patel PR. A large outbreak of hepatitis C virus infections in a hemodialysis clinic. Infect Control Hosp Epidemiol 2016;37(2):125–33. DOI PubMed

11. Perz JF, Thompson ND, Schaefer MK, Patel PR. US outbreak investigations highlight the need for safe injection practices and basic infection control. Clin Liver Dis 2010;14(1):137–51. DOI PubMed

12. Macedo de Oliveira A, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, Perz JF, Safranek TJ. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005;142(11):898–902. DOI PubMed

13. Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med 2009;150(1):33–9. DOI PubMed

14. Savey A, Simon F, I佐met J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 2005;26(9):752–60. DOI PubMed

15. Toronto Public Health. HCV outbreak investigation - North Scarborough Endoscopy Clinic Final Report. Toronto (ON): Toronto Public Health; 2014.

16. Toronto Public Health. HCV outbreak investigation - Ontario Endoscopy Clinic Final Report. Toronto (ON): Toronto Public Health; 2015.

17. Government of Ontario. Health Protection and Promotion Act, R.S.O. 1990, c. H.7. 2015:1-59. Toronto (ON): Government of Ontario; 2020 (accessed 2019-12-24). https://www.ontario.ca/laws/statute/90h07?search=Public+Health+Act&use_exact=on

18. Ontario Ministry of Health and Long-Term Care. Ontario Public Health Standards: Requirements for programs, services, and accountability (Standards). Toronto (ON): Government of Ontario; 2018.

19. Centers for Disease Control and Prevention. Viral hepatitis: Health-care investigation guide. Atlanta (GA): CDC; 2015 (accessed 2019-12-21). http://www.cdc.gov/hepatitis/Outbreaks/HealthcareInvestigationGuide.htm

20. Bornschlegel K, Dentinger C, Layton M, Balter S, France AM; Centers for Disease Control and Prevention (CDC). Investigation of viral hepatitis infections possibly associated with health-care delivery—New York City, 2008–2011. MMWR Morb Mortal Wkly Rep 2012;61(19):333–8. PubMed
21. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Labstract: Hepatitis C virus (HCV) RNA and genotype testing and interpretation. Toronto (ON): Public Health Ontario; 2008 (updated 2019-12; accessed 2020-11-07). https://www.publichealthontario.ca/-/media/documents/lab/lab-sd-033-hep-c-rna-testing-update.pdf?la=en

22. Provincial Infectious Diseases Advisory Committee. Infection prevention and control for clinical office practice. Toronto (ON): Public Health Ontario; 2013 (accessed 2019-12-24). https://www.publichealthontario.ca/-/media/documents/b/2013/bp-clinical-office-practice.pdf?la=en

23. College of Physicians and Surgeons of Ontario. Out-of-Hospital Premises Inspection Program (OPHIP) Program Standards. Toronto (ON): CPSO; 2013 (updated 2017-10). https://www.cpsso.on.ca/admin/CPSO/media/Documents/physician/your-practice/quality-in-practice/clinic-inspection-s-special-programs/ophip-standards.pdf

24. Greeley RD, Semple S, Thompson ND, High P, Rudowski E, Handschur E, Guo-Liang X, Ganova-Raeva L, Crawford J, Roberts C, Tan C, Montana B. Hepatitis B outbreak associated with a hematology-oncology office practice in New Jersey, 2009. Am J Infect Control 2011;39(8):663–70. DOI PubMed

25. County of Los Angeles Public Health. 2010 Pain Clinic Hepatitis Investigation Report – OB 201016. Los Angeles (CA): County of Los Angeles Public Health; 2011. http://publichealth.lacounty.gov/acd/docs/HeptInfo/Final Report Hepatitis Investigation at Pain Clinic.pdf.pdf

26. Comstock RD, Mallonee S, Fox JL, Moolenaar RL, Vogt TM, Perz JF, Bell BP, Crutcher JM. A large nosocomial outbreak of hepatitis C and hepatitis B among patients receiving pain remediation treatments. Infect Control Hosp Epidemiol 2004;25(7):576–83. DOI PubMed

27. Centers for Disease Control and Prevention (CDC). Notes from the field: deaths from acute hepatitis B virus infection associated with assisted blood glucose monitoring in an assisted-living facility—North Carolina, August–October 2010. MMWR Morb Mortal Wkly Rep 2011;60(6):182. PubMed

28. Centers for Disease Control and Prevention (CDC). Hepatitis C virus transmission at an outpatient hemodialysis unit—New York, 2001-2008. MMWR Morb Mortal Wkly Rep 2009;58(8):189–94. DOI PubMed

29. Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis 2004;38(11):1592–8. DOI PubMed

30. Schaefer MK, Jhung M, Dahl M, Schillie S, Simpson C, Llata E, Link-Gelles R, Sinkowitz-Cochran R, Patel P, Bolyard E, Selulster L, Srinivasan A, Perz JF. Infection control assessment of ambulatory surgical centers. JAMA 2010;303(22):2273–9. DOI PubMed

31. Facility Guidelines Institute. Guidelines for design and construction of hospitals and outpatient facilities. Chicago (IL): American Hospital Association; 2014.

32. Government of Ontario. Excellent Care for All Act, 2010, S.O. 2010, c. 14.; 2014. Toronto (ON): Government of Ontario; 2020 (accessed 2019-12-21). https://www.ontario.ca/laws/statute/10e14

33. Government of Ontario. Ontario Regulation 490/09: Designated Substances; 2013:21. http://www.ellaws.gov.on.ca/html/regs/english/elaws_regs_090490_e.htm#

34. Rotermann M, Langlois K, Andonov A, Trubnikov M. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 2013;24(11):3–13. PubMed

35. Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190(22):E677–87. DOI PubMed

36. Cadieux G, Brown C, Sachdeva H. Public health investigation of infection prevention and control complaints in Ontario, 2015-2018. Can Commun Dis Rep 2019;45(11):289–95. DOI PubMed